Hepatitis B Core Antibody Level: A Surrogate Marker for Host Antiviral Immunity in Chronic Hepatitis B Virus Infections
Curious4:33CCAI
paperi.ai
0:00 / 0:00
Yang Shi, Zihan Wang, Shengxiang Ge, Ningshao Xia, Quan Yuan
A routine blood antibody may reveal more than whether hepatitis B was ever present. Its level may act like a dashboard for how strongly the body is fighting the virus—and how likely treatment is to help.
The hepatitis B virus core protein (HBcAg) is a highly immunogenic particulate antigen. Nearly all patients with persistent or resolved hepatitis B virus (HBV) infection show seropositivity for hepatitis B core antibody (anti-HBc), which appears in the early stage of infection and is mostly present for life. Traditionally, the anti-HBc is regarded as an evidential serological marker of HBV infections. In the last ten years, several studies revealed the predictive value of quantitative anti-HBc (qAnti-HBc) level in the treatment response and clinical outcome of chronic HBV infections, implying new insights into this classic marker. Overall, qAnti-HBc should be regarded as an indicator of the host’s immune response specific to HBV, which correlates with HBV-related hepatitis activity and liver pathology. This review summarized the latest understanding of the clinical values of qAnti-HBc for differentiating the CHB phase, predicting treatment response, and providing disease prognosis. Moreover, we also discussed the possible mechanism of qAnti-HBc regulation during different courses of HBV infection.
Transcript
A routine blood antibody may reveal more than whether hepatitis B was ever present. Its level may act like a dashboard for how strongly the body is fighting the virus—and how likely treatment is to help. Hepatitis B can lead to cirrhosis and liver cancer.
It is mainly passed from mother to child, and it can also spread through blood or sexual contact. About 296 million people worldwide live with chronic hepatitis B, and about 800,000 people die from related diseases each year. Vaccination has greatly reduced new infections, but current drugs cannot completely eradicate the virus, so many people with chronic infection still face liver-disease risk.
Because current treatment has limits and chronic hepatitis B can change over many years, better blood markers are crucial. They can help guide treatment, predict prognosis, and support clinical management. Quantitative core antibody is an established hepatitis B marker, and studies have revealed new roles for measuring its level quantitatively in clinical assessment.
The body's virus-fighting cells could reveal its immune response, but in chronic infection those cells are often worn out and difficult to detect in ordinary clinical practice. Other antibodies are less useful as an all-purpose signal: one usually appears only after the infection has resolved, while another appears in only some patients.
The core antibody can be detected through nearly all phases of infection. It can record more than whether infection ever happened: anti-HBc identifies past or ongoing infection, and its level often exceeds qualitative assay limits.
People in the immune-active phase, when hepatitis is present, typically have about ten times higher core-antibody levels than people in phases without hepatitis. Studies link higher core-antibody levels with increased ALT activity in blood and with more severe liver inflammation seen in biopsy tissue.
Its link with liver scarring is weaker than its link with inflammation, suggesting that inflammation is the clearer signal for this marker. Because liver inflammation usually comes from immune-driven liver injury, a high core-antibody level reflects the body's immune response against hepatitis B.
In chronic hepatitis B, the immune response aimed at the virus’s inner core remains active, while the response to its outer surface becomes worn down. That may explain why core-directed antibodies track immune activity, whereas surface-directed defenses struggle to produce effective protection.
Across extensive studies, a high core-antibody level strongly predicted E-antigen seroconversion, a change associated with a favorable prognosis and reduced progressive liver inflammation and advanced liver disease. Among people whose blood contained the E antigen, higher core-antibody levels were linked with a greater chance of this change after treatment with two types of hepatitis B medicine.
The core-antibody level is a well-validated predictor of this change, whether it happens naturally or after treatment, among people whose blood contains the E antigen. People with higher core-antibody levels have a greater chance of achieving it.
Different studies found slightly different thresholds, but a range around 10,000 to 30,000 units per millilitre may suit adults with chronic hepatitis B. In chronic hepatitis B, the core-antibody level serves as a surrogate marker for the body's antiviral immune activity against the virus.
During E-antigen-positive phases of chronic infection, elevated core-antibody-associated antiviral immune activity can help drive immunological control against hepatitis B. But during E-antigen-negative phases, the same raised immune activity can instead signal hepatitis caused by the immune system escaping control.
The test is not ready to answer every clinical question: automatic testing is not standardized, and well-validated cutoffs for different situations are still missing. Better evidence could help optimize chronic hepatitis B care. The core-antibody level is a useful sign of the body's hepatitis B immune activity, linked to liver inflammation and treatment response.
It could help guide care, although testing standards still need improvement.
A derivative work by Paperi · AI-generated script, voice and captions
· pages and figures unaltered
Made with Paperi.
Drop in a research PDF — get a narrated video walkthrough like this one,
with highlights that follow the narration. Free to start.
Mohamad Khalil, Patrizia Gena, Agostino Di Ciaula, Piero Portincasa, Giuseppe Calamita
Bile is almost entirely water, yet tiny water channels may help decide whether it flows normally, concentrates safely, or contributes to disease. This review asks whether those channels could become treatment targets.Bile is about ninety-five percent water, yet tiny membrane channels help decide how that water moves through the liver, bile ducts, and gallbladder. This review asks whether those channels could become therapeutic targets.
For some children, staying alive can mean lying under special blue lights for ten to twelve hours every day. This review asks whether future treatments could repair the problem instead of managing it for life.A rare genetic disorder can force children to spend ten to twelve hours a day under phototherapy—and for the most severe form, the only definitive cure is a liver transplant. This review asks what could come next.
Bowel cancer is rising in lower- and middle-income countries, and this study finds that the share linked with diet increased across all 21 countries examined. What we eat may be part of a changing regional health story.Across the Middle East and North Africa, the burden of colorectal cancer linked to dietary risk increased from 1990 to 2019. The pattern was especially pronounced among men, older adults, and several countries in the region.
5:56
